Señales en vivo de OTIC | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (11 abr 2023 @ 15:58):

Stats
Volumen de hoy	1.94M
Volumen promedio	876 957
Capitalización de mercado	582 482
EPS	$0 ( 2023-11-08 )
Last Dividend	$0.110 ( 2023-04-11 )
Next Dividend	$0 ( N/A )
P/E	-0.142
ATR14	$0.00500 (58.82%)

Insider Trading

Date	Person	Action	Amount	type
2023-02-15	Hogan H Michael Iii	Buy	0
2022-12-30	Weber David Allen	Sell	91 636	Common Stock
2022-12-28	Cayer Paul E	Sell	40 054	Common Stock
2022-11-28	Capps Vickie L	Sell	42 242	Common Stock
2022-06-21	Schroeder Theodore R	Buy	27 500	Stock Option (right to buy)

INSIDER POWER
-37.51
Last 98 transactions
Buy: 7 968 332 \| Sell: 3 029 863

Volumen Correlación

Largo: 0.68 (moderate)

Corto: -0.97 (very strong negative)

Signal:(8.549) Possible Trading Opportunity Present (swing)

Otonomy Inc Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Otonomy Inc Correlación - Moneda/Commodity

-0.16
( neutral )

-0.27
( neutral )

0.00
( neutral )

0.25
( neutral )

Otonomy Inc Finanzas

Annual	2021
Ingresos:	$125 000
Beneficio Bruto:	$-245 000 (-196.00 %)
EPS:	$-0.810

FY	2021
Ingresos:	$125 000
Beneficio Bruto:	$-245 000 (-196.00 %)
EPS:	$-0.810

FY	2020
Ingresos:	$273 000
Beneficio Bruto:	$-915 000 (-335.16 %)
EPS:	$-1.100

FY	2019
Ingresos:	$600 000
Beneficio Bruto:	$-312 000 (-52.00 %)
EPS:	$-1.450

Financial Reports:

No articles found.

Otonomy Inc Dividends

(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0.110 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Otonomy Inc Dividend Information - Dividend Knight

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.110	2023-04-11
Last Dividend	$0.110	2023-04-11
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.110	--
Avg. Dividend % Per Year	39.17%	--
Score	4.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-05-06)

$0.220 Estimate 2.50 %

Dividend Stability

0.20 Very Poor

Dividend Score

4.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2023	$0.110	117.50%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXSQ	Dividend Royal	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-402.60	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.526	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	0.0949	1.500	-0.0565	-0.0848	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	6.52	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	6.28	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	6.28	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.166	-1.500	7.24	-10.00	[0 - 0.6]
interestCoverageTTM	-31.04	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.669	2.00	-0.223	-0.446	[0 - 30]
freeCashFlowPerShareTTM	-0.673	2.00	-0.337	-0.673	[0 - 20]
debtEquityRatioTTM	-0.0285	-1.500	-0.114	0.171	[0 - 2.5]
grossProfitMarginTTM	-1.960	1.000	-10.00	-10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-397.00	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-2.68	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.00131	0.800	-3.32	-2.66	[0.5 - 2]
Total Score				-3.12

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.0107	1.000	-0.102	0	[1 - 100]
returnOnEquityTTM	0.0949	2.50	-0.0363	-0.0848	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.673	2.00	-0.224	-0.673	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.669	2.00	-0.223	-0.446	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-339.34	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-1.609

Otonomy Inc

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.